Below is a list of resources compiled by CSRC members to guide you on cardiac safety, drug development, and its relation to COVID-19. Click on the hyperlinks below to access journal articles and other academic materials.
Cardiovascular Risk Management
- HRS COVID19 Task Force Message: General Guidance for QTc Monitoring in COVID-19 Patients
- Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19
- Troponin and BNP Use in COVID-19
- Role of the American Heart Association in the Global COVID-19 Pandemic
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
- COVID-19 Clinical Guidance For the Cardiovascular Care Team
- Preserving Clinical Trial Integrity During the Coronavirus Pandemic
- ACC - Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19
- HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
- Multi-lead QT Screening Necessary for QT Measurement
- ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic
CV Risk of compounds been used to treat COVID-19 (Hydroxychloroquine, Chloroquine, Azithromycin)
- Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Hydroxychloroquine Sulfate Supplied from the Strategic National Stockpile for Treatment of COVID-19 in Certain Hospitalized Patients
- Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
- Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia
- Toxicokinetics of hydroxychloroquine following a massive overdose
- Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine
- Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment
- Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects
- Long QT and Hydroxychloroquine; A Poorly Recognised Problem In Rheumatology Patients
- ZITHROMAX FDA Label
- Hydroxychloroquine Label
- Chloroquine Label
- FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems
DDIs
Selected clinical study reports of CV risk in COVID-19 patients
- The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin
- Prevalence of QT Interval Prolongation in Patients Admitted to Cardiac Care Units and Frequency of Subsequent Administration of QT Interval-Prolonging Drugs
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China
- ACE ARBs COVID Circulation Research April 2020